Advertisement

Effects of d-Propranolol Treatment on Transport of Thyroid Hormones into Tissue Cells

  • Roelof Docter
  • Johannes T. M. van der Heijden
  • Eric P. Krenning
  • Georg Hennemann

Abstract

It is well known that treatment with d,1-propranolol elicits a low T3 syndrome in man (1,2). This has been explained by the assumption of an inhibition of 5’-deiodinase in the liver by d,l-propranolol, leading to a diminished production of T3 from T4 and a diminished breakdown of rT3. However, the Ki of d,l-propranolol on this enzyme in vitro is about 0.8 mM (3), (3), while therapeutic levels of this compound are between 0.5 and 1 µM in serum (4), and, at least in the rat, the liver does not concentrate propranolol (5). Recently, it has been shown that a derivative, 4-OH-propranolol, markedly inhibits 5’-deiodinase activity in vitro at a concentration of about 50 µM (6), but the concentration in serum is below 50 nM (6). Inhibition of the enzyme in vivo seems, therefore, questionable. On the other hand, we have found that transport of iodothyronines into rat liver hepatocytes in primary culture is strongly inhibited by propranolol in a concentration of only 1 µM (7). Furthermore, we have shown that at least part of the low T3 syndrome, elicited by caloric deprivation, can be attributed to inhibition of transport of T4 into the liver (8). Therefore, we have performed tracer T4, T3, and rT3 kinetic studies to investigate if the low T3 syndrome elicited by propranolol is caused by transport inhibition of T4 and rT3 into the liver, or by inhibition of conversion of T4 to T3 and rT3 to T2.

Keywords

Mass Transfer Rate Propranolol Treatment Deiodinase Activity Slow Pool Caloric Deprivation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lumholtz IB, Siersbaek-Nielsen K, Faber J, et al. J Clin Endocrinol Metab 47: 587, 1978.PubMedCrossRefGoogle Scholar
  2. 2.
    Verhoeven RP, Visser TJ, Docter R, et al. J Clin Endocrinol Metab 44: 1002, 1977.PubMedCrossRefGoogle Scholar
  3. 3.
    Fekkes D, Hennemann G, and Visser TJ. Bioch Pharmacol 31: 1705, 1982.CrossRefGoogle Scholar
  4. 4.
    Shand DG, Nuckolls EM, and Dates JA. Clin Pharmacol Therp 11: 112, 1970.Google Scholar
  5. 5.
    Bianchetti G, Elghozi JL, Gomeni R, et al. J Pharmacol Exp Therap 214: 682, 1980.Google Scholar
  6. 6.
    Jorgensen PH, Lumholtz IB, Faber J, et al. Acta Endocrinol (khhn) 105: 205, 1984.Google Scholar
  7. 7.
    Krenning EP, Docter R, Visser TJ, et al. J Endocrinol Invest 6: 59, 1983.PubMedGoogle Scholar
  8. 8.
    Docter R, Van der Heijden JTM, Krenning EP, et al. Annal d’Endocrinol 45: 76A, 1984.Google Scholar
  9. 9.
    Greenwood FC, Hunter WM, and Glover JS. Biochem J 89: 144, 1963.Google Scholar
  10. 10.
    Bianchi R, Zucchelli GC, Giannessik D, et al. J Clin Endocrinol Metab 46: 203, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    DiStefano III JJ, Jang M, Malone TK, et al. Endocrinology 110: 198, 1982.PubMedCrossRefGoogle Scholar
  12. 12.
    DiStefano III JJ, Malone TK, and Jang M. Endocrinology 111: 108, 1982.PubMedCrossRefGoogle Scholar
  13. 13.
    Bauer ACG, Wilson JHP, Lamberts SWJ, et al. Submitted for publication, 1985.Google Scholar
  14. 14.
    Nies AS, Evans GH, and Shand DG. J Pharmacol Exp Therap 184: 716, 1973.Google Scholar
  15. 15.
    Nies AS, Evans GH, and Shand DG. Am Heart J 85: 97, 1973.PubMedCrossRefGoogle Scholar
  16. 16.
    Shand DG. Postgrad Med J 52 (suppl. 4): 22, 1976.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • Roelof Docter
    • 1
  • Johannes T. M. van der Heijden
    • 1
  • Eric P. Krenning
    • 1
  • Georg Hennemann
    • 1
  1. 1.Dept. of Internal Medicine III and Nuclear MedicineErasmus UniversityRotterdamThe Netherlands

Personalised recommendations